Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

A number of other research firms also recently issued reports on SYRS. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Syros Pharmaceuticals currently has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Trading Down 8.2 %

Shares of Syros Pharmaceuticals stock opened at $0.23 on Tuesday. The firm has a market capitalization of $6.17 million, a price-to-earnings ratio of -0.08 and a beta of 1.34. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a 12-month low of $0.18 and a 12-month high of $8.17. The firm’s 50 day simple moving average is $0.87 and its two-hundred day simple moving average is $2.58.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period last year, the business earned ($1.35) earnings per share. Analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Activity at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.26% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SYRS. Acadian Asset Management LLC grew its holdings in shares of Syros Pharmaceuticals by 101.5% in the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC acquired a new stake in shares of Syros Pharmaceuticals during the 2nd quarter worth about $109,000. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals during the third quarter worth about $34,000. Finally, Exome Asset Management LLC lifted its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares during the last quarter. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.